A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Phase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson#s Disease Experiencing End-of-Dose #We

Grants and Contracts Details

StatusFinished
Effective start/end date6/3/15 → 7/9/18

Funding

  • Biotie Therapeutics Incorporated: $66,804.00